Replies to post #10218 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

2 recent filings. I- Insider bought 150,000 shares @ $0.065. II-12M additional shares issued and financial statements 'updated'. Dilution is inconsequential at this point. Funds raised are insufficient for any meaningful business initiative. Note that inventory on balance sheet contains no finished goods for sale.